ALK-Abello AS 2011 AR2
The report highlights ALK's strong financial performance in 2011, achieving record revenue and earnings despite challenging market conditions. It outlines the company's global growth strategy, including key partnerships in North America and Japan to expand its tablet-based allergy vaccine portfolio. In terms of corporate social responsibility, ALK adopted a new CSR policy focusing on allergy prevention, ethical conduct, employee safety, and environmental impact. The company successfully maintained its energy consumption at 2008 levels and reduced its CO2 emissions by 3% through increased use of renewable energy.
Company: ALK-Abello AS
Sector: Health Care
Country: Denmark
Year: 2011
Type: AR2
Pages: 86
ALK-Abello AS
Annual Report
The report highlights ALK's strong financial performance in 2011, achieving record revenue and earnings despite challenging market conditions. It outlines the company's global growth strategy, including key partnerships in North America and Japan to expand its tablet-based allergy vaccine portfolio. In terms of corporate social responsibility, ALK adopted a new CSR policy focusing on allergy prevention, ethical conduct, employee safety, and environmental impact. The company successfully maintained its energy consumption at 2008 levels and reduced its CO2 emissions by 3% through increased use of renewable energy.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2011
Reporting Period
Jan 1, 2011 - Dec 31, 2011
Fiscal Year
2011
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees